Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIA
2023-508828-35-01Phase 3Completed
- Sponsor
- SOLTI
- Start
- Sep 2024
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ribociclib, palbociclib and odronextamab in breast cancer (3 arms), sponsored by SOLTI. Primary endpoint: Progression-free survival. Started Sep 2024; status: completed.
02
Drugs
ribociclibpalbociclibodronextamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508828-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508828-35-01.